These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26687339)

  • 21. Impact of baseline lipoprotein and C-reactive protein levels on coronary atheroma regression following high-intensity statin therapy.
    Puri R; Nissen SE; Shao M; Uno K; Kataoka Y; Kapadia SR; Tuzcu EM; Nicholls SJ
    Am J Cardiol; 2014 Nov; 114(10):1465-72. PubMed ID: 25282317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparision of high sensitivity C-reactive protein and matrix metalloproteinase 9 in patients with unstable angina between with and without significant coronary artery plaques.
    Wang LX; Lü SZ; Zhang WJ; Song XT; Chen H; Zhang LJ
    Chin Med J (Engl); 2011 Jun; 124(11):1657-61. PubMed ID: 21740772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Atorvastatin (10 mg) and Ezetimibe (10 mg) Combination Compared to Atorvastatin (40 mg) Alone on Coronary Atherosclerosis.
    Oh PC; Jang AY; Ha K; Kim M; Moon J; Suh SY; Lee K; Han SH; Kang WC
    Am J Cardiol; 2021 Sep; 154():22-28. PubMed ID: 34238445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrated Biomarker and Imaging Study 3 (IBIS-3) to assess the ability of rosuvastatin to decrease necrotic core in coronary arteries.
    Oemrawsingh RM; Garcia-Garcia HM; van Geuns RJ; Lenzen MJ; Simsek C; de Boer SP; Van Mieghem NM; Regar E; de Jaegere PP; Akkerhuis KM; Ligthart JM; Zijlstra F; Serruys PW; Boersma E
    EuroIntervention; 2016 Aug; 12(6):734-9. PubMed ID: 27542785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients.
    Saeedi R; Johns K; Frohlich J; Bennett MT; Bondy G
    Lipids Health Dis; 2015 Jun; 14():57. PubMed ID: 26087958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of fluvastatin on progression of coronary atherosclerotic plaque evaluated by virtual histology intravascular ultrasound.
    Nasu K; Tsuchikane E; Katoh O; Tanaka N; Kimura M; Ehara M; Kinoshita Y; Matsubara T; Matsuo H; Asakura K; Asakura Y; Terashima M; Takayama T; Honye J; Hirayama A; Saito S; Suzuki T
    JACC Cardiovasc Interv; 2009 Jul; 2(7):689-96. PubMed ID: 19628194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
    Puri R; Nissen SE; Libby P; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Circulation; 2013 Nov; 128(22):2395-403. PubMed ID: 24043299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study.
    Kovarnik T; Mintz GS; Skalicka H; Kral A; Horak J; Skulec R; Uhrova J; Martasek P; Downe RW; Wahle A; Sonka M; Mrazek V; Aschermann M; Linhart A
    Circ J; 2012; 76(1):176-83. PubMed ID: 22076422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes of coronary plaque composition correlate with C-reactive protein levels in patients with ST-elevation myocardial infarction following high-intensity statin therapy.
    Koskinas KC; Zaugg S; Yamaji K; García-García HM; Taniwaki M; Klingenberg R; Moschovitis A; Lüscher TF; van Tits LJ; Matter CM; Windecker S; Räber L
    Atherosclerosis; 2016 Apr; 247():154-60. PubMed ID: 26921743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal.
    Laires PA; Ejzykowicz F; Hsu TY; Ambegaonkar B; Davies G
    J Med Econ; 2015; 18(8):565-72. PubMed ID: 25788039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris.
    Fukuda D; Shimada K; Tanaka A; Kusuyama T; Yamashita H; Ehara S; Nakamura Y; Kawarabayashi T; Iida H; Yoshiyama M; Yoshikawa J
    Am J Cardiol; 2006 Jan; 97(2):175-80. PubMed ID: 16442358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).
    Ballantyne CM; Weiss R; Moccetti T; Vogt A; Eber B; Sosef F; Duffield E;
    Am J Cardiol; 2007 Mar; 99(5):673-80. PubMed ID: 17317370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Remnant Lipoprotein on Coronary Plaque Components.
    Matsuo N; Matsuoka T; Onishi S; Yamamoto H; Kato A; Makino Y; Kihara S
    J Atheroscler Thromb; 2015 Aug; 22(8):783-95. PubMed ID: 25739822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy of eicosapentaenoic acid and pitavastatin for coronary plaque regression evaluated by integrated backscatter intravascular ultrasonography (CHERRY study)-rationale and design.
    Watanabe T; Miyamoto T; Miyasita T; Shishido T; Arimoto T; Takahashi H; Nishiyama S; Hirono O; Matsui M; Sugawara S; Ikeno E; Miyawaki H; Akira F; Kubota I
    J Cardiol; 2014 Sep; 64(3):236-9. PubMed ID: 24503140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.
    Li L; Zhang M; Su F; Li Y; Shen Y; Shen J; Zhang D
    Lipids Health Dis; 2015 Feb; 14():10. PubMed ID: 25879728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of combined ezetimibe and statin therapy versus statin therapy alone on coronary plaque volume assessed by intravascular ultrasound: A systematic review and meta-analysis.
    Mirzaee S; Thein PM; Nogic J; Nerlekar N; Nasis A; Brown AJ
    J Clin Lipidol; 2018; 12(5):1133-1140.e15. PubMed ID: 30318063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors underlying regression of coronary atheroma with potent statin therapy.
    Puri R; Nissen SE; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; St John J; Wolski K; Uno K; Kataoka Y; Nicholls SJ
    Eur Heart J; 2013 Jun; 34(24):1818-25. PubMed ID: 23644179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fixed-dose combination of rosuvastatin and ezetimibe: treating hypercholesteremia according to cardiovascular risk.
    Barrios V; Escobar C
    Expert Rev Clin Pharmacol; 2021 Jul; 14(7):793-806. PubMed ID: 33970743
    [No Abstract]   [Full Text] [Related]  

  • 39. Statin/ezetimibe combination therapy vs statin monotherapy for carotid atherosclerotic plaque inflammation.
    Oh M; Kim H; Shin EW; Sung C; Kim DH; Moon DH; Lee JS; Lee PH; Lee SW; Lee CW
    Medicine (Baltimore); 2021 Mar; 100(10):e25114. PubMed ID: 33725908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of intensive lipid lowering on lipid profiles over time and tolerability in stable coronary artery disease: insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).
    Kawashiri MA; Yamagishi M; Sakamoto T; Takayama T; Hiro T; Daida H; Hirayama A; Saito S; Yamaguchi T; Matsuzaki M;
    Cardiovasc Ther; 2013 Dec; 31(6):335-43. PubMed ID: 23409830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.